Target intelligence / Profile preview

Polyribosylribitol phosphate (PRP)

Target
PRP
Molecular classification
Other
01

Overview

Polyribosylribitol phosphate (PRP) is the linear capsular polysaccharide (poly-3-beta-D-ribosyl-(1->1)-D-ribitol-5-phosphate) of Haemophilus influenzae type b (Hib), a Gram-negative bacterium responsible for severe invasive infections such as meningitis, pneumonia, bacteremia, and epiglottitis, primarily in infants and young children. PRP acts as the major virulence factor of Hib by inhibiting phagocytosis and allowing the bacterium to evade the host immune system. In its native form, PRP is a T-cell-independent antigen that fails to elicit a robust or long-lasting immune response in infants under two years of age due to their immature immune systems. To overcome this limitation, PRP is chemically conjugated to carrier proteins (such as tetanus toxoid, diphtheria toxoid, or meningococcal outer membrane protein complex) to create glycoconjugate vaccines. This conjugation converts PRP into a T-cell-dependent antigen, which successfully recruits T-helper cells, promotes class switching to high-affinity IgG antibodies, and establishes immunological memory. Widespread immunization with Hib conjugate vaccines has dramatically reduced the incidence of invasive Hib disease globally.

Other names
Haemophilus influenzae type b capsular polysaccharideHaemophilus influenzae type b capsular polysaccharide PRP epitopesPoly-3-beta-D-ribosyl-(1->1)-D-ribitol-5-phosphateHib capsular polysaccharideHib PRPPolyribosyl-ribitol-phosphate
02

Mechanism of action

Active immunization via glycoconjugate vaccines where PRP is covalently linked to a carrier protein. This chemical conjugation converts the T-cell-independent PRP polysaccharide into a T-cell-dependent antigen, recruiting T-helper cells to stimulate B-cell activation, class switching to high-affinity IgG antibodies, and the establishment of long-term immunological memory.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionInflammation
05

Safety considerations

Injection site reactions (pain, erythema, swelling)Systemic reactions (fever, irritability, somnolence, loss of appetite)Hypersensitivity or anaphylaxisHypotonic-hyporesponsive episodes (HHE)Reduced immunogenicity of the Hib component when co-administered in certain acellular pertussis-containing combination vaccines
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Anti-PRP IgG antibody concentration (>= 0.15 mcg/mL for short-term protection, >= 1.0 mcg/mL for long-term protection)Anti-PRP antibody aviditySerum bactericidal activity (SBA)

Beyond the preview

Go deeper on Polyribosylribitol phosphate (PRP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyribosylribitol phosphate (PRP).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call